Abiopharma

🔍 Swain Carol (Director)

Company: NexPoint Real Estate Finance, Inc. (NREF)

Report Date: 2026-04-02

Detailed Transactions and Holdings:

• Acquired 5,518 shares of Common Stock (Direct)
  Date: 2026-04-03 | Code: M | equity_swap_involved: 0 | shares_owned_after: 14,322.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 2,759 shares of Common Stock (Direct)
  Date: 2026-04-03 | Code: D | equity_swap_involved: 0 | shares_owned_after: 11,563.00 | transaction_form_type: 4 | Footnotes: F2
• Acquired 6,154 shares of Restricted Stock Units (Derivative)
  Date: 2026-04-02 | Code: A | equity_swap_involved: 0 | shares_owned_after: 6,154.00 | transaction_form_type: 4 | Footnotes: F1, F3, F3
• Sold 5,518 shares of Restricted Stock Units (Derivative)
  Date: 2026-04-03 | Code: M | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1, F4, F4

Footnotes:

• F1: Each restricted stock unit represents a contingent right to receive one share of common stock of NexPoint Real Estate Finance, Inc.
• F2: Represents the portion of the previously reported restricted stock unit grant that vested on April 3, 2026 and settled in cash.
• F3: On April 2, 2026, the reporting person was granted 6,154 restricted stock units, which vest on April 2, 2027. Settlement will generally occur within 30 days of vesting and may at the discretion of the Compensation Committee be settled in cash.
• F4: On April 3, 2025, the reporting person was granted 5,518 restricted stock units, which vested on April 3, 2026. Settlement will generally occur within 30 days of vesting and may at the discretion of the Compensation Committee be settled in cash.